Abstract:In oncology dose-finding clinical trials, the key to accurately estimating the maximum tolerated dose (MTD) is to use all data efficiently given small sample sizes. Currently, popular designs dichotomize adverse events of various types and grades that occur within the first treatment cycle into binary toxicity outcomes of dose-limiting toxicity (DLT) events. Such compression of toxicity data from multiple treatment cycles causes huge loss of information, often resulting in MTD estimation with large bias and variance. To improve this, a continuous endpoint (the total toxicity profile, TTP) was proposed to incorporate adverse event types and grades. The Bayesian Repeated Measures Design (RMD) was further developed by Yin et al. (2017) to account for the cumulative toxicity information from multiple treatment cycles. However, the existing RMD method selects the dose that minimizes the loss function based on point estimates, which may generate inconsistent results due to small sample sizes in phase I trials. To reduce the variability in dose escalation decision-making, we propose an improved repeated measures design with an interval-based decision rule that selects the dose with the highest posterior probability of falling in a pre-specified target toxicity interval. Through comprehensive simulations, we compared this proposed design with the existing RMD design, along with well-established DLT-based designs such as Continual Reassessment Method (CRM) and Bayesian Logistic Regression Model (BLRM). The results demonstrated that our proposed design outperforms all other designs in terms of accurately identifying the MTD and assigning fewer patients to sub-therapeutic or overly toxic doses.

MT-Keyboard: A Bayesian Model-assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials

Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials

MC-Keyboard: A Practical Phase I Trial Design for Targeted Therapies and Immunotherapies Integrating Multiple-Grade Toxicities

Gboin: a Unified Model-Assisted Phase I Trial Design Accounting for Toxicity Grades, and Binary or Continuous End Points

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

TITE‐BOIN12: A Bayesian Phase I/II Trial Design to Find the Optimal Biological Dose with Late‐onset Toxicity and Efficacy

Comparative Review of Novel Model‐assisted Designs for Phase I Clinical Trials

Comparative review of novel model-assisted designs for phase I clinical trials.

Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

Utpi: A Utility‐based Toxicity Probability Interval Design for Phase I/II Dose‐finding Trials

Bayesian Interval-Based Oncology Dose-Finding Design with Repeated Quasi-Continuous Toxicity Model

Enhancing phase I dose-finding trials design through dynamic borrowing information and handling late-onset toxicity

Statistical Properties of the Keyboard Design with Extension to Drug-Combination Trials

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

On the Relative Efficiency of Model-Assisted Designs: a Conditional Approach.

Incorporating Historical Information to Improve Phase I Clinical Trials

A Bayesian Design for Finding Optimal Biological Dose with Mixed Types of Responses of Toxicity and Efficacy.